OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Semrad on SPIDER Program to Understand Resistance to Therapies

October 5th 2015

Thomas J. Semrad, MD, assistant professor, co-director, Phase I Program, UC Davis Health System, discusses the Serial Patient-Derived Xenografts to Understand Cancer Therapy Resistance (SPIDER) program at UC Davis Health System, aimed at understanding patient resistance to cancer therapies.

Dr. Ferrari on LBH589 and Bicalutamide in CRPC

October 2nd 2015

Anna C. Ferrari, MD, professor, co-director, GU Research Program, Departments of Medicine (Cancer Center) and Medicine (Residency Program), discusses a study that examined the efficacy of LBH589 and bicalutamide in patients with castration-resistant prostate cancer.

Moon Chen on Disparities in Cancer Care

October 1st 2015

Moon S. Chen Jr., PhD, MPH, associate director, Population Research and Cancer Disparities, professor, UC Davis Comprehensive Cancer Center, discusses various disparities in cancer care in underserved populations.

Dr. Morris on Lymphopenia as a Predictor of Survival in CRT-Treated NSCLC

September 30th 2015

John Morris, MD, professor of Medicine, co-director, Comprehensive Lung Cancer Center, associate director, UCCI Translational Research and Director, Experimental Therapeutics, University of Cincinnatti, discusses lymphopenia as a predictor of survival in chemoradiation-treated non–small cell lung cancer.

Jason Matney on Deep Inspiration Breath Hold During Radiation Therapy for Breast Cancer

September 29th 2015

Jason Matney, PhD, clinical assistant professor, Physics and Computing Division, Department of Radiation Oncology, UNC School of Medicine, discusses a prospective assessment of deep inspiration breath hold to prevent radiation-associated cardiac perfusion defects in patients with left-sided breast cancer.

Dr. Chan on ExteNET Trial for HER2+ Breast Cancer

September 27th 2015

Arlene Chan, MD, director, Mount Hospital at Perth, discusses the ExteNET trial, which looked at neratinib as extended adjuvant therapy in patients with early-stage HER2-positive breast cancer.

Dr. Boughey on Locoregional Trials for Breast Cancer

September 27th 2015

Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses locoregional clinical trials for breast cancer.

T.S. Wiley on Bio-identical Hormone Replacement Therapy for Patients With Breast Cancer

September 27th 2015

T.S. Wiley, CEO, Wiley Protocol Systems, discusses a study that examined the efficacy of biomemetic bio-identical hormone replacement therapy for patients with metastatic breast cancer.

Dr. Kapoor on Multigene Panel Testing for Patients at Risk for Breast Cancer

September 26th 2015

Nimmi S. Kapoor, MD, surgical oncologist, Breastlink Laguna Hills and Breastlink Orange, discusses the benefits and safety of multigene panel testing in patients who are at risk for hereditary breast cancer.

Dr. Szeja on Adjuvant Radiation Therapy After Lumpectomy in Elderly Patients With TNBC

September 26th 2015

Sean Szeja, MD, radiation oncologist, University of Texas Medical Branch, discusses outcomes associated with adjuvant radiation therapy following lumpectomy for elderly patients with triple-negative breast cancer.

Dr. Sherwell-Cabello on Prognostic Impact of TILs and SILs in TNBC

September 26th 2015

Santiago Sherwell-Cabello, MD, breast surgical oncology, Instituto de Enfermedades de la Mama, discusses the prognostic impact of tumor-infiltrating lymphocytes and stromal-infiltrating lymphocytes in patients with triple-negative breast cancer (TNBC).

Dr. Daly on Clinical Trials With Radiation Therapy in Lung Cancer

September 24th 2015

Megan E. Daly, MD, assistant professor of radiation oncology, UC Davis Cancer Center, discusses upcoming clinical trials involving radiation therapy for the treatment of lung cancer.

Dr. Mell on Toxicities Associated With GL-ONC1 for Head and Neck Cancer

September 23rd 2015

Loren K. Mell, MD, chief, Head and Neck Malignancy Service, associate professor, University of California, San Diego, discusses toxicities associated with GL-ONC1 for the treatment of patients with head and neck cancer.

Dr. Tahir Latif on Lower Male Survival Rates in Diffuse Large B-cell Lymphoma

September 22nd 2015

Tahir Latif, MD, associate professor of Medicine, interim chief, Division of Hematology Oncology, director, Infusion Services University of Cincinnati Cancer Institute, discusses differences in male survival rates versus female among patients with diffuse large B-cell lymphoma (DLBCL).

Jeanine Stiles on the Importance of Supportive Care for Patients With Cancer

September 22nd 2015

Jeanine Stiles, chief administrative officer, associate director for administration, UC Davis Comprehensive Cancer Center, discusses the importance of supportive care for patients with cancer.

Dr. Patt on Impact of Healthcare Reform Changes on Oncology Care

September 21st 2015

Debra Patt, MD, physician, Texas Oncology, discusses the current healthcare reform changes and what effects they will have on oncology care.

Dr. Roth Compares Surgery With SBRT in Lung Cancer

September 18th 2015

Jack A. Roth, MD, professor, Department of Thoracic and Cardiovascular Surgery, chief, Section of Thoracic Molecular Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, compares surgery with stereotactic body radiation therapy (SBRT) in patients with early-stage lung cancer.

Dr. Carraway on Aza-Nucleoside Combinations in MDS

September 18th 2015

Hetty Carraway, MD, Hematology and Oncology, Cleveland Clinic, discusses combination epigenetic therapies including aza-nucleosides and histone deacetylase inhibitors, as well as immunomodulatory therapies, such as lenalidomide for the treatment of myelodysplastic syndromes (MDS).

Dr. Luke Discusses Combination Approaches on Horizon in Melanoma

September 17th 2015

Jason J. Luke, MD, assistant professor of Medicine, University of Chicago Medicine, discusses combination approaches that are on the horizon for the treatment of patients with melanoma.

Dr. Wierda on Minimal Residual Disease in CLL

September 17th 2015

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses minimal residual disease in chronic lymphocytic leukemia (CLL). 

NEXT PAGE
PREVIOUS PAGE